GlassScriptPhysician profile
Nadia G Ledesma
NPI 1477006989
$400.84
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $205.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $116.24 | 2022 | |
| Abbvie INC. | $45.86 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.89 | 2022 | |
| Alkermes, INC. | $40.07 | 2021 | |
| Viiv Healthcare Company | $33.09 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $27.09 | 2021 | |
| Glaxosmithkline, LLC. | $21.16 | 2022 | |
| Boston Scientific Corporation | $21.09 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.14 | 2021 | |
| Corium, LLC | $14.33 | 2022 | |
| Dexcom, INC. | $13.47 | 2021 | |
| Lilly USA, LLC | $12.41 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Ledesma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.